Edition:
United States

Biotechnology & Medical Research

Immunicum Q1 Operating Loss At SEK 29.1 Million

April 25 (Reuters) - Immunicum AB ::REG-IMMUNICUM AB (PUBL) INTERIM REPORT JANUARY - MARCH 2019.Q1 OPERATING LOSS SEK 29.1 MILLION VERSUS LOSS SEK 28.8 MILLION YEAR AGO.Q1 EARNINGS AND DILUTED EARNINGS PER SHARE TOTALED SEK -0,3 (-0,6).

2:00am EDT

IXICO Says FY Revenues Will Be In Line With Market Expectations Of 6.6 Mln Stg

April 25 (Reuters) - IXICO PLC ::TRADING UPDATE FOR FIRST HALF OF FINANCIAL YEAR ENDING 31 MARCH 2019.ON TRACK TO DELIVER ROBUST REVENUE GROWTH FROM £21.2M ORDER BOOK.STRONG CLOSING CASH BALANCE OF £7.5M AS AT 31 MARCH 2019.REPORTED REVENUES EXPECTED TO BE £3.43M FOR 6 MONTHS TO 31 MARCH 2019 (2018:...

2:00am EDT

Oryzon Reaches Primary Endpoint In Phase IIa Trial For ADHD

April 25 (Reuters) - Oryzon Genomics SA ::SAID ON WEDNESDAY IT REACHED A PRIMARY ENDPOINT IN PHASE IIA TRIAL FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD).TO CONTINUE DEVELOPMENT OF VAFIDEMSTAT IN PSYCHIATRIC INDICATIONS.VAFIDEMSTAT PRODUCED SIGNIFICANT IMPROVEMENTS IN ADHD PATIENTS ACROSS...

12:28am EDT

Expansion & New Markets

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.